Loading...
Loading...
Array Biopharma Inc
ARRY shares dropped 7.1% to $6.25 following AstraZeneca plc's report of Phase 3 SUMIT metastatic uveal melanoma study. Share volume totaled 343,000, compared to an all-day average of 478,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
